Jonathan Lambert

And most recently, HHS has started offering $25,000 to employees of that agency, and that's part of HHS, if they leave. And there are also rumblings of some senior scientist contracts not being renewed.

And most recently, HHS has started offering $25,000 to employees of that agency, and that's part of HHS, if they leave. And there are also rumblings of some senior scientist contracts not being renewed.

And most recently, HHS has started offering $25,000 to employees of that agency, and that's part of HHS, if they leave. And there are also rumblings of some senior scientist contracts not being renewed.

So the NIH had been blocked from reviewing new grants, but that's been partially lifted. So that whole process of reviewing grant applications has restarted to some degree. At the same time, though, a lot of existing grants have been terminated to comply with the president's executive orders, barring anything related to DEI and the LGBTQ community.

So the NIH had been blocked from reviewing new grants, but that's been partially lifted. So that whole process of reviewing grant applications has restarted to some degree. At the same time, though, a lot of existing grants have been terminated to comply with the president's executive orders, barring anything related to DEI and the LGBTQ community.

So the NIH had been blocked from reviewing new grants, but that's been partially lifted. So that whole process of reviewing grant applications has restarted to some degree. At the same time, though, a lot of existing grants have been terminated to comply with the president's executive orders, barring anything related to DEI and the LGBTQ community.

Right. Trump picked Dr. Jay Bhattacharya from Stanford to take over the agency. He's a very well-respected health economist with a strong record of high-quality research. But he has also been a vocal critic of the NIH, most notably during the pandemic. He argued against measures like lockdowns.

Right. Trump picked Dr. Jay Bhattacharya from Stanford to take over the agency. He's a very well-respected health economist with a strong record of high-quality research. But he has also been a vocal critic of the NIH, most notably during the pandemic. He argued against measures like lockdowns.

Right. Trump picked Dr. Jay Bhattacharya from Stanford to take over the agency. He's a very well-respected health economist with a strong record of high-quality research. But he has also been a vocal critic of the NIH, most notably during the pandemic. He argued against measures like lockdowns.

During his confirmation hearing last week, he promised to create a more open environment at the NIH for what he called dissenting views. And Baudetoria is expected to be easily confirmed. So everyone's waiting to see what he does and bracing for the possibility of more cuts and possibly even a major restructuring. The question is, how radical will those reforms be and how will they be done?

During his confirmation hearing last week, he promised to create a more open environment at the NIH for what he called dissenting views. And Baudetoria is expected to be easily confirmed. So everyone's waiting to see what he does and bracing for the possibility of more cuts and possibly even a major restructuring. The question is, how radical will those reforms be and how will they be done?

During his confirmation hearing last week, he promised to create a more open environment at the NIH for what he called dissenting views. And Baudetoria is expected to be easily confirmed. So everyone's waiting to see what he does and bracing for the possibility of more cuts and possibly even a major restructuring. The question is, how radical will those reforms be and how will they be done?

And, you know, science is an international enterprise, and the U.S. is a leader internationally when it comes to scientific research. So the real concern is, where is this going to go? And is this U.S. going to be giving up that position in the world?

And, you know, science is an international enterprise, and the U.S. is a leader internationally when it comes to scientific research. So the real concern is, where is this going to go? And is this U.S. going to be giving up that position in the world?

And, you know, science is an international enterprise, and the U.S. is a leader internationally when it comes to scientific research. So the real concern is, where is this going to go? And is this U.S. going to be giving up that position in the world?

Good to be here. Thanks, Emily.

Good to be here. Thanks, Emily.

Good to be here. Thanks, Emily.

On Sunday at noon Eastern, the NSF said that the agency will resume distributing funds to scientists who had received grants. They have been unable to access their funds since Tuesday when the agency froze payments as they reviewed how their grants complied with new executive orders, especially those targeting diversity, equity, and inclusion.

On Sunday at noon Eastern, the NSF said that the agency will resume distributing funds to scientists who had received grants. They have been unable to access their funds since Tuesday when the agency froze payments as they reviewed how their grants complied with new executive orders, especially those targeting diversity, equity, and inclusion.